America’$ Rehab Dream –
July 3, 2020 – Recent developments in the COVID-19 pandemic have led to increased drug addiction relapses. Hence, companies in the addiction treatment market are capitalizing on the demand for drugs and are increasing their production capabilities. However, many manufacturing units have been temporarily shut down which has led to supply shocks in most hospitals and retail pharmacies. Addiction treatment medications are deemed essential goods and hence governments are relaxing lockdown regulations to resume manufacturing in production units.
Individuals with opioid use disorder and methamphetamine use disorder are most vulnerable to acquire the Coronavirus infection since their pulmonary and respiratory systems are potentially weak. Though e-cigarettes reduce exposure to harmful combustion, the aerosols and nicotine in these cigarettes cause harm to human health, resulting in increased demand for addiction treatment medicines.
Competition Landscape of the Addiction Treatment Market
Some of the established companies profiled in this Fact.MR study include, but are not limited to Orexo AB, Alkermes, Recket Benckiser (Indivior), Teva Pharmaceuticals, and Purdue Pharma. Top tier companies in the addiction treatment market are focusing on expanding their distribution chains for acamprosate and varenicline. They are increasing their R&D activities to validate the safety of varenicline amongst smoking addicted patients. Medtech companies are innovating in very low nicotine content cigarettes to help individuals self-administer their cravings and bolster cessation rates.